Programme death ligand 1 expressions as a surrogate for determining immunotherapy in cervical carcinoma patients

BACKGROUND: The programme death ligand1 and its receptor (PD-1/PD-L1) interaction is a target for blockage by immunotherapy that uses the body’s own immune system. Some studies show that PD-L1 expressing tumours are also more aggressive with poor prognosis. This study evaluated the immunohistochemic...

Descripción completa

Detalles Bibliográficos
Autores principales: Omenai, Sebastian A., Ajani, Mustapha A., Okolo, Clement A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8827435/
https://www.ncbi.nlm.nih.gov/pubmed/35139126
http://dx.doi.org/10.1371/journal.pone.0263615

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8827435/
https://www.ncbi.nlm.nih.gov/pubmed/35139126
http://dx.doi.org/10.1371/journal.pone.0263615

Ejemplares similares